A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
Results from a retrospective review demonstrated that administration of neoadjuvant tyrosine kinase inhibitor therapy can effectively downstage patients with unresectable differentiated thyroid cancers, allowing patients to achieve R0...
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
According to results from a multi-cohort study, lenvatinib plus pembrolizumab demonstrated efficacy and safety among patients with progressive, radioiodine-refractory differentiated thyroid cancer.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
